XML 55 R45.htm IDEA: XBRL DOCUMENT
v3.21.2

Identifiable Intangible Assets - Additional Information (Detail) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Amortization of intangible assets useful life |  |  | 10 years |
Amortization of intangible assets | $ 199 | $ 251 | $ 613 | $ 758
Impairment of intangible assets excluding goodwill | $ 21 | 509 | 295 | 1,278
In Process Research And Development To Product Rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Prior periods adjustments |  |  | 162 |
lenalidomide [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Prior periods adjustments |  |  | $ 123 |
Minimum [Member] | Measurement input, discount rate [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 0.073 |  | 0.073 |
Maximum [Member] | Measurement input, discount rate [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 0.078 |  | 0.078 |
In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  | 360 |  | 708
In Process Research and Development [Member] | Minimum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 0.0725 |  | 0.0725 |
In Process Research and Development [Member] | Minimum [Member] | Measurement input, discount rate [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 20 |  | 20 |
In Process Research and Development [Member] | Maximum [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 0.10 |  | 0.10 |
In Process Research and Development [Member] | Maximum [Member] | Measurement input, discount rate [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination, contingent consideration, liability, measurement input | 90 |  | 90 |
In Process Research and Development [Member] | Lenalidomide Product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  | 262 |  | 262
In Process Research and Development [Member] | Generic Pipeline Products [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | $ 86 |
Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  |  | 570
Identifiable product rights [Member] | Lenalidomide Product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | 30 |
Identifiable product rights [Member] | Metformin tablets product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  | 110 |  | 110
Actavis [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination recognized identifiable assets | $ 589 |  | 589 |
Actavis [Member] | In Process Research and Development [Member] | Generic Pipeline Products [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  | 96 |  | 213
Actavis [Member] | Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  | 149 | 209 |
AUSTEDO [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  |  | 211
Japan [Member] | Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  |  | 165
United States [Member] | Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  | $ 39 |  |
United States [Member] | Actavis [Member] | Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | $ 179 | $ 271

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of assets acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of a reclassification adjustment made to prior period financial statement amounts. + References No definition available. + Details
Name: | us-gaap_PriorPeriodReclassificationAdjustment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ReclassificationTypeAxis=teva_InProcessResearchAndDevelopmentToProductRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReclassificationTypeAxis=teva_LenalidomideMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_LenalidomideProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_GenericPipelineProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_MetforminTabletsProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_ActavisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AustedoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |